Arunava Goswami
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Arunava Goswami has a total of 168 co-authors. Here are the top co-authors by number of shared publications:
- Moumita Sil
Biological Science Division, Indian Statistical Institute, 203 B. T. Road, Kolkata 700108, West Bengal, India
13 shared publications Moumita Sil
7 shared publicationsAnamitra Goswami
Department of Life Science and Biochemistry, St. Xavier's College (Autonomous), 5, Mahapalika Marg, Mumbai, India
5 shared publicationsNabanita Mukherjee
Department of Zoology, Jangipur College
5 shared publicationsAyesha Rahman
Indian Statistical Institute, Biological Sciences Division
4 shared publicationsPrashant Ratnaparkhi
Department of Life Science and Biochemistry, St. Xavier's College (Autonomous), 5, Mahapalika Marg, Mumbai, India
4 shared publications
Latest Publications
- 24 August 2026
- Published by Springer Nature in Indian Journal of Microbiology
- p. 1-10
Nanomedicine from Ayurvedic Medicinal Plants
- 24 August 2026
- Published by Springer Nature in Indian Journal of Microbiology
- p. 1-10
Nanomedicine from Ayurvedic Medicinal Plants
- 8 April 2026
- Published by Springer Nature in Circular Economy and Sustainability
- Vol. 6 (2)
Development of Circular Economy Based Ecosystem with Nanofertilizers
- 8 April 2026
- Published by Springer Nature in Circular Economy and Sustainability
- Vol. 6 (2)
Development of Circular Economy Based Ecosystem with Nanofertilizers
- 16 February 2026
- Published by American Chemical Society (ACS) in ACS Agricultural Science & Technology
- Vol. 6 (4) , 561-574
Effects of Mesoporous Silica Nanoparticles on Seedling Growth of Vigna radiata and Glycolytic Metabolism in Bacillus coagulans
- 16 February 2026
- Published by American Chemical Society (ACS) in ACS Agricultural Science & Technology
- Vol. 6 (4) , 561-574
Effects of Mesoporous Silica Nanoparticles on Seedling Growth of Vigna radiata and Glycolytic Metabolism in Bacillus coagulans
- Open Access
- 13 February 2026
- Published by Elsevier in Next Nanotechnology
- Vol. 9
Antimicrobials from nano sulfur: Innovations, applications, and future perspectives
- 13 February 2026
- Published by Elsevier in Next Nanotechnology
- Vol. 9
Open AccessAntimicrobials from nano sulfur: Innovations, applications, and future perspectives
- 5 February 2026
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 41 (1) , 30
The gut–brain axis in arsenic-induced toxicity: mechanisms, consequences, and therapeutic perspectives
Chronic ingestion of arsenic frequently occurring in contaminated groundwater poses a serious dual threat to neurological health. Environmental toxicants present in groundwater are highly correlated with onset of neuropathological effects through complex gut-brain axis interactions. The systematic review of literature aims evaluate the neurobehavioural consequences and molecular outcome of a groundwater contaminant, arsenic with microbiota alteration involving animal studies and epidemiological data. Arsenic disrupts the gut microbiota, diminishing beneficial bacteria and promoting harmful strains, which in turn compromise gut barrier integrity, trigger inflammation and oxidative stress, leading to alteration in critical metabolic pathways involved in neurotransmitter production and mitochondrial function. Animal studies have shown that chronic exposure intensifies these effects, causing more pronounced microbial dysbiosis alongside worsened cognitive and behavioural deficits. Mechanistically, arsenic impairs neural signaling by elevating reactive oxygen species, disrupting synaptic and mitochondrial dynamics, and inducing neuroinflammation after its accumulation in brain tissues, while gut-derived neuroactive compounds exacerbate neuroinflammation and neuronal damage irrespective of significant arsenic deposition in the brain. Therapeutic strategies that reinforce gut health, such as targeted probiotic and prebiotic supplementation have demonstrated the ability to restore microbiome balance, strengthen barrier function, reduce neuroinflammatory markers and improve behavioural outcomes in experimental models. These microbiota-focused interventions, when combined with conventional measures like chelation to remove toxic metals and the deployment of water treatment infrastructure in affected regions, suggest a powerful integrated approach. By addressing both the source of contamination and the downstream biological consequences, this multimodal strategy holds significant promise for mitigating arsenic-induced neurotoxicity and protecting at-risk populations in affected communities.
- 5 February 2026
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 41 (1) , 30
The gut–brain axis in arsenic-induced toxicity: mechanisms, consequences, and therapeutic perspectives
Chronic ingestion of arsenic frequently occurring in contaminated groundwater poses a serious dual threat to neurological health. Environmental toxicants present in groundwater are highly correlated with onset of neuropathological effects through complex gut-brain axis interactions. The systematic review of literature aims evaluate the neurobehavioural consequences and molecular outcome of a groundwater contaminant, arsenic with microbiota alteration involving animal studies and epidemiological data. Arsenic disrupts the gut microbiota, diminishing beneficial bacteria and promoting harmful strains, which in turn compromise gut barrier integrity, trigger inflammation and oxidative stress, leading to alteration in critical metabolic pathways involved in neurotransmitter production and mitochondrial function. Animal studies have shown that chronic exposure intensifies these effects, causing more pronounced microbial dysbiosis alongside worsened cognitive and behavioural deficits. Mechanistically, arsenic impairs neural signaling by elevating reactive oxygen species, disrupting synaptic and mitochondrial dynamics, and inducing neuroinflammation after its accumulation in brain tissues, while gut-derived neuroactive compounds exacerbate neuroinflammation and neuronal damage irrespective of significant arsenic deposition in the brain. Therapeutic strategies that reinforce gut health, such as targeted probiotic and prebiotic supplementation have demonstrated the ability to restore microbiome balance, strengthen barrier function, reduce neuroinflammatory markers and improve behavioural outcomes in experimental models. These microbiota-focused interventions, when combined with conventional measures like chelation to remove toxic metals and the deployment of water treatment infrastructure in affected regions, suggest a powerful integrated approach. By addressing both the source of contamination and the downstream biological consequences, this multimodal strategy holds significant promise for mitigating arsenic-induced neurotoxicity and protecting at-risk populations in affected communities.
- 29 December 2025
- Published by Springer Nature in BioNanoScience
- Vol. 16 (1) , 75
Convergence in Nanomedicine: Integrating Brain-Targeted Delivery and Gut Microbiota Modulation for Neurological Protection
- 29 December 2025
- Published by Springer Nature in BioNanoScience
- Vol. 16 (1) , 75
Convergence in Nanomedicine: Integrating Brain-Targeted Delivery and Gut Microbiota Modulation for Neurological Protection
- 6 December 2025
- Published by Springer Nature in Molecular Neurobiology
- Vol. 63 (1) , 264
Chamomile Modulates Glucose Metabolism and Neuro-inflammation to Alleviate Stress-Induced Depression in Mice
Depression, a common psychiatric condition, is frequently associated with chronic stress. This research investigates the therapeutic benefit of chamomile (Matricaria chamomilla) against restraint stress (RS)-induced behavioral and neurobiological alterations in male mice. Animals were categorized into control, RS, and RS + chamomile (Cm) groups. Behavioral evaluation (open field, rotarod, catalepsy, memory test), histopathology, integrity of the blood-brain barrier, and gene expression profiling were done. In silico ProTox analysis confirmed the non-toxicity of chamomile compounds, including chamazulene, which also complies with Lipinski's Rule of Five, indicating drug-like properties. Molecular docking identified robust interactions between chamazulene and prominent stress-related and other relevant targets like IFN-γ, IL-6, caspase-3, BDNF, and GLUT-1. RS exposure interfered with locomotor activity, evoked neuroinflammation, apoptosis, and compromised neuronal-glial function. Treatment with chamomile greatly enhanced locomotor function and posture, decreased catalepsy latency test, and normalized neuronal architecture. Immunofluorescence staining and transcriptional analysis indicated that chamomile suppressed pro-inflammatory cytokines (IFN-γ, IL-6), the apoptotic marker Caspase-3, and increased neurotrophic and neuronal markers (BDNF, NeuN, GFAP) and glycolytic enzymes (GLUT-1, HK-1, LDHA). These results indicate that chamomile has neuroprotective actions by regulating RS-induced inflammation, apoptosis, and metabolic dysfunction. Although no remarkable effects were seen on body or brain-to-body weight ratio, chamomile exhibited powerful behavioral and molecular effects. Overall, the results highlight chamomile, particularly its active constituent chamazulene, as a promising candidate for alleviating restraint stress. However, further clinical validation is required to establish its therapeutic potential in neuropsychiatric disorders.
- 6 December 2025
- Published by Springer Nature in Molecular Neurobiology
- Vol. 63 (1) , 264
Chamomile Modulates Glucose Metabolism and Neuro-inflammation to Alleviate Stress-Induced Depression in Mice
Depression, a common psychiatric condition, is frequently associated with chronic stress. This research investigates the therapeutic benefit of chamomile (Matricaria chamomilla) against restraint stress (RS)-induced behavioral and neurobiological alterations in male mice. Animals were categorized into control, RS, and RS + chamomile (Cm) groups. Behavioral evaluation (open field, rotarod, catalepsy, memory test), histopathology, integrity of the blood-brain barrier, and gene expression profiling were done. In silico ProTox analysis confirmed the non-toxicity of chamomile compounds, including chamazulene, which also complies with Lipinski's Rule of Five, indicating drug-like properties. Molecular docking identified robust interactions between chamazulene and prominent stress-related and other relevant targets like IFN-γ, IL-6, caspase-3, BDNF, and GLUT-1. RS exposure interfered with locomotor activity, evoked neuroinflammation, apoptosis, and compromised neuronal-glial function. Treatment with chamomile greatly enhanced locomotor function and posture, decreased catalepsy latency test, and normalized neuronal architecture. Immunofluorescence staining and transcriptional analysis indicated that chamomile suppressed pro-inflammatory cytokines (IFN-γ, IL-6), the apoptotic marker Caspase-3, and increased neurotrophic and neuronal markers (BDNF, NeuN, GFAP) and glycolytic enzymes (GLUT-1, HK-1, LDHA). These results indicate that chamomile has neuroprotective actions by regulating RS-induced inflammation, apoptosis, and metabolic dysfunction. Although no remarkable effects were seen on body or brain-to-body weight ratio, chamomile exhibited powerful behavioral and molecular effects. Overall, the results highlight chamomile, particularly its active constituent chamazulene, as a promising candidate for alleviating restraint stress. However, further clinical validation is required to establish its therapeutic potential in neuropsychiatric disorders.
- 27 July 2025
- Published by Springer Nature
- p. 191-222
Introduction to Biological Network
- 12 July 2025
- Published by Springer Nature in Journal of Molecular Neuroscience
- Vol. 75 (3) , 1-34
Glial Cells in Alzheimer’s Disease: Pathogenic Mechanisms and Therapeutic Frontiers
The rising incidence of brain diseases parallels the global trend of an aging population, with Alzheimer’s disease (AD) being a leading neurodegenerative disorder characterized by memory loss, dementia, and cognitive decline. Despite extensive research, current treatments for AD remain largely symptomatic and have had limited success in halting disease progression, thereby shifting attention toward glial cells as promising therapeutic targets due to their emerging roles in AD pathogenesis. Astrocytes are involved in both beneficial and pathological processes in AD, such as cytokine secretion, Aβ removal, metabolic support, and tau pathology, with deficiency resulting in neuroinflammation and excitotoxicity. Microglia have dual functions in AD by phagocytosing amyloid plaques and limiting tau spread in initial phases but may develop a pro-inflammatory, neurodegenerative phenotype with progression of the disease. Oligodendrocytes and their precursors are involved in Aβ generation and myelin homeostasis, and their disturbance is responsible for white matter lesions and cognitive impairment, though their exact mechanisms are less clear. This review also examines emerging therapeutic strategies targeting glial cells, including modulating TREM2 pathways and novel drug candidates. These methods highlight the therapeutic value of the glial cells and provide valuable leads for furthering the treatment of AD by elucidating their changing roles in the course of the disease. Graphical Abstract
- 12 July 2025
- Published by Springer Nature in Journal of Molecular Neuroscience
- Vol. 75 (3) , 1-34
Glial Cells in Alzheimer’s Disease: Pathogenic Mechanisms and Therapeutic Frontiers
The rising incidence of brain diseases parallels the global trend of an aging population, with Alzheimer’s disease (AD) being a leading neurodegenerative disorder characterized by memory loss, dementia, and cognitive decline. Despite extensive research, current treatments for AD remain largely symptomatic and have had limited success in halting disease progression, thereby shifting attention toward glial cells as promising therapeutic targets due to their emerging roles in AD pathogenesis. Astrocytes are involved in both beneficial and pathological processes in AD, such as cytokine secretion, Aβ removal, metabolic support, and tau pathology, with deficiency resulting in neuroinflammation and excitotoxicity. Microglia have dual functions in AD by phagocytosing amyloid plaques and limiting tau spread in initial phases but may develop a pro-inflammatory, neurodegenerative phenotype with progression of the disease. Oligodendrocytes and their precursors are involved in Aβ generation and myelin homeostasis, and their disturbance is responsible for white matter lesions and cognitive impairment, though their exact mechanisms are less clear. This review also examines emerging therapeutic strategies targeting glial cells, including modulating TREM2 pathways and novel drug candidates. These methods highlight the therapeutic value of the glial cells and provide valuable leads for furthering the treatment of AD by elucidating their changing roles in the course of the disease. Graphical Abstract